Last reviewed · How we verify
I.V ampicillin 2 gram x4/d for 2 days
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking. Used for Bacterial infections susceptible to ampicillin (e.g., respiratory tract infections, urinary tract infections, meningitis, endocarditis), Gram-positive and some gram-negative bacterial infections.
At a glance
| Generic name | I.V ampicillin 2 gram x4/d for 2 days |
|---|---|
| Sponsor | Western Galilee Hospital-Nahariya |
| Drug class | Beta-lactam antibiotic (aminopenicillin) |
| Target | Penicillin-binding proteins (PBPs); bacterial peptidoglycan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ampicillin is a beta-lactam antibiotic that irreversibly inhibits transpeptidase enzymes responsible for cross-linking peptidoglycan strands in the bacterial cell wall. This disruption of cell wall integrity leads to bacterial cell lysis and death. It is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections susceptible to ampicillin (e.g., respiratory tract infections, urinary tract infections, meningitis, endocarditis)
- Gram-positive and some gram-negative bacterial infections
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reaction / anaphylaxis
- Vomiting
- Abdominal pain
Key clinical trials
- Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: